BioSpace News Archive

Lunit, a global provider of AI-powered cancer solutions, announced strong financial results for the second quarter of the fiscal year 2022.

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an update on corporate activities.

Humana Inc. (NYSE: HUM) announced today that it will acquire substantially all of the assets of Inclusa, Inc., a Managed Care Organization (“MCO”) in Wisconsin that provides long-term care services and supports to approximately 16,600 older adults and adults with disabilities through the state’s Family Care program.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), today announced financial results for the quarter ended June 30, 2022, and provided an update on its clinical programs.

Hospital for Special Surgery, the academic medical center specialized in musculoskeletal care since 1863, announced the appointment of Sheeraz Qureshi, MD, MBA as co-chief of HSS Spine, effective October 1, 2022.

Amid signs that a more severe influenza season is approaching in the US, a panel of public health leaders urged that people get vaccinated in preparation for the upcoming influenza season and warned that patients in high-risk populations tend to suffer significant flu-related health disparities.3

Piedmont Orthopedics | OrthoAtlanta has opened a new location, at 1700 Tree Lane, Suite 300 in Snellville.

Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), today reported financial results for the second quarter ended June 30, 2022 and provided business updates.

Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., today announced that it will present results from its Phase 2 VISIONARY-MS trial at 7:30 a.m. EDT on Monday, August 15.

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.